Kiniksa Pharmaceuticals International, plc
KNSA
Rangering i aksjer
#2875
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aksjekurs
$83.13
Sist synkronisert: 2026-10-20
Markedsverdi
$6.49B
Endring (1 dag)
4.59%
Endring (1 år)
113.97%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Historikk for aksjesplitt for Kiniksa Pharmaceuticals International, plc (KNSA)
Aksjen Kiniksa Pharmaceuticals International, plc (symbol: KNSA) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én KNSA-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 KNSA-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én KNSA-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 KNSA-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 0 | - |
US
|
|
| 0 | - |
SE
|
|
| 0 | - |
FR
|
|
| 0 | - |
IT
|
|
| 0 | - |
US
|
